Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes ...

NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors ...

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

BIOS/UEFI vulnerabilities in the iSeq 100 DNA sequencer from U.S. biotechnology company Illumina could let attackers disable ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

A consignment of fermenting machines at the heart of a new penicillin plant under development at Sohar Freezone – the first ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The CBI has stepped up its probe into the alleged financial irregularities in Delhi Public Works Department (PWD) projects between 2012 and 2019, with probe agency booking 11 officials and a ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...